Precision radiation for prostate cancer shows promise in early trial
NCT ID NCT02470897
First seen Jun 26, 2026 · Last updated Jun 26, 2026
Summary
This study tested a new way to deliver radiation for prostate cancer. The goal was to give a higher dose to the tumor while protecting the urethra and other healthy tissue. 115 men with early-stage prostate cancer took part. The researchers looked at side effects and how well the treatment worked over time.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- radiation therapy (SBRT with IMRT planning)
- What this could lead to
- If successful, this approach could offer a shorter, more precise radiation treatment for prostate cancer with fewer side effects.
- What could go wrong
- This is an early-phase study focused on safety and dosing, so it's not yet proven to be better than standard radiation. There is still a risk of urinary or rectal side effects.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for STAGE I PROSTATE ADENOCARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Swedish American
Rockford, Illinois, 61104, United States
-
UW Cancer Center, Johnson Creek
Johnson Creek, Wisconsin, 53038, United States
-
University of Wisconsin Carbone Cancer Center
Madison, Wisconsin, 53792, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.